Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis

Sponsor
Changhai Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05183425
Collaborator
(none)
60
1
36
1.7

Study Details

Study Description

Brief Summary

Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. Tumor heterogeneity is the cause of treatment failure. In this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
The Exploratory Study of Patient-derived Organoids for the Prediction and Evaluation of Clinical Efficiency Effect of Colorectal Cancer Liver Metastasis
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2024

Outcome Measures

Primary Outcome Measures

  1. The consistency of drug sensitivity [3 years]

    To test the consistency of drug sensitivity of primary tumor and its matched liver metastasis

Secondary Outcome Measures

  1. The establishment of PDO [3 years]

    To test the rate of PDO derived from primary and matched metastatic colorectal cancer .

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Histologically proven colorectal cancer with liver metastasis

  • Aged between 18 and 70 years

  • Written informed and signed consent

  • Accessible to surgery sample of metastasis and primary tumor

Exclusion Criteria:
  • Less than 18 years and older than 70 years

  • Not able to give informed consent

  • Not accessible to surgery sample

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Colorectal Surgery in Changhai Hospital Shanghai Shanghai China 200433

Sponsors and Collaborators

  • Changhai Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wei Zhang, Director of the department of colorectal surgery, Changhai Hospital
ClinicalTrials.gov Identifier:
NCT05183425
Other Study ID Numbers:
  • CHCS-PDO
First Posted:
Jan 10, 2022
Last Update Posted:
Feb 4, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 4, 2022